Abstract: Cannabinoid-loaded formulations are characterized by including 0.5 wt. % to 20 wt. % medium chain triglycerides, one or more hydrophilic surfactants, one or more co-surfactants and 0.1 wt. % or more of at least one cannabinoid. The formulations are in microemulsion form, and are fully dilutable by an aqueous diluent.

Abstract: A cosmetic composition includes an antimicrobial system that includes an antimicrobial agent comprising 4-hydroxyacetophenone and one or more additional antimicrobial agents comprising piroctone olamine. The antimicrobial system can be used in a cosmetic composition wherein the composition is a makeup removal composition that is one of an O/W emulsion, a W/O emulsion, a micellar water, a makeup removing wipe, or a two-phase (or multi-phase) composition. The antimicrobial system may be free or essentially free of any one or more of parabens, alcohols, formaldehyde, and formaldehyde-derived compounds. In some particular embodiments, the composition is free or essentially free of parabens, formaldehyde, formaldehyde-derived compounds, pentylene glycol, phenoxyethanol, hexylglycerin, ethylhexylglycerin, octylglycerin, benzylglycerin, 3-heptoyl-2,2-propandiol, and 1,2-hexandiol.

Abstract: Provided are cannabinoid-loaded, dilutable microemulsion formulations with low oil content including oleic acid and linoleic acid.

Abstract: Cosmetic compositions, kits thereof, and methods of making and using such cosmetic compositions. The cosmetic compositions typically include about 20 to about 95 wt. % of a polyol; about 5 to about 70 wt. % of one or more monoalcohols having from 2 to 6 carbon atoms; about 0.1 to about 10 wt. % of one or more cationic surfactants; about 0.1 to about 20 wt. % of one or more fatty compounds; and about 1 to about 15 wt. % of a combination of a urea compound and citric acid, wherein all weight percentages are based on the total weight of the cosmetic composition. The cosmetic compositions have a weight ratio of polyol to monoalcohol(s) that is from 20:1 to 1:20. Additionally, the cosmetic compositions typically have a mole ratio of citric acid to urea compound of that is about 10:0.5 to about 0.5:10.

Abstract: A composition for reducing unpleasant odor, the composition includes betaine; musk; and N-Soya-N-ethyl morpholinium ethosulfate.

Abstract: An antiperspirant and/or deodorant composition including from 0.01 weight % to 0.15 weight % flaxseed oil and from 0.5 weight % to 5.0 weight % taurine.

Abstract: A cosmetic composition comprising, in an aqueous cosmetically acceptable medium: a) from 6% to 50% by weight in active material of at least one aqueous polyurethane dispersion; and b) from 2% to 8% by weight of at least one cross-linked starch, the weight being expressed by weight of the total weight of the composition.

Abstract: Provided is an oral soft gel capsule that includes a psychedelic compound. Also provided is a method of treating in a subject a disease or disorder ameliorated by a psychedelic compound, that includes orally administering to a subject an oral soft gel capsule that includes a therapeutically effective amount of the psychedelic compound. Also provided is a method of orally administering to a subject an oral soft gel capsule that includes a therapeutically effective amount of the psychedelic compound. Also provided is a method of orally administering to a subject an oral soft gel capsule that includes a low dose (e.g., microdose or sub-therapeutic dose) of the psychedelic compound.

Abstract: Described is a cannabinoid-terpenoid solution (CTS) and method of treating a disease state or condition in animals other than humans via cannabinoid-terpenoid therapy. The CTS includes a unique combination of cannabinoids, terpenoids (terpenes), and a lipophilic carrier to allow safely and effectively treat the animal.

Abstract: Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (Cmax) of at least 30 ng/mL, with (b) a mean time to Cmax (Tmax) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.

Abstract: The present invention relates to a composition for stimulating muscle growth, repair and maintenance and the method of using the same. The present invention generally relates to compositions and methods for supporting muscle anabolism. The compositions described herein are pharmaceutical or nutritional compositions suitable for preserving muscle mass, strength, and/or function in a subject in need thereof. The compositions are based on a specially formulated mixture of essential amino acids (EAAs) and protein with additional components. Use of the compositions herein may prevent muscle atrophy associated with periods of rest, such as those following surgery, injury, inactivity and during recovery from disease.

Abstract: Transdermal therapeutic system for the transdermal administration of a systemically active agent comprising a self-adhesive layer structure, comprising A) a backing layer, and B) a dried biphasic layer, the dried biphasic layer having a) an outer phase having a composition comprising 75% to 100% of a polymer or polymer mixture, and b) an inner phase having a composition comprising at least one active agent, wherein the inner phase forms dispersed deposits in the outer phase, and c) 0.1% to 3.5% of an interface mediator with a kinematic viscosity of from 10 cSt to 100 000 cSt at 25° C., and C) optionally an additional skin contact layer.

Abstract: A kit, compositions, and methods of treatment for skin basal cell and squamous cell carcinomas The compositions include caustic and base parts. In a broad embodiment, the caustic part includes oxalic acid dihydrate 4-6 wt/vol %, lactic acid 90% 0.5-2 wt/vol %, pyruvic acid 0.20-0.90 wt/vol %, acetic acid 2-6 wt/vol %, nitric acid 65% 30-60 wt/vol %, trichloracetic acid 2-4 wt/vol %, and distilled water to 100%. In the broad embodiment, the base part includes cetyl alcohol 3-5 wt/vol %, glyceryl monostearate (GMS) 2-4 wt/vol %, ritachol-1000 (emulsifier) 10-20 wt/vol %, dimethicone (200/200 fluid) 3-7 wt/vol %, sesame oil 3-7 wt/vol %, hyaluronic acid sodium salt 0.2-0.5 wt/vol %, xanthan gum 0.1-0.3 wt/vol %, polyethylene glycol-400 5-15 wt/vol %, titanium dioxide 0.2-0.6 wt/vol %, preservative complex 4-8 wt/vol %, phenoxyethanol 0.5-3 wt/vol %, sodium sulfite (Na2SO3) 0.5-4, and distilled water to 100%.

Abstract: A nanotherapeutic having platinum complexes encapsulated by a nanoformulation containing at least one spinel ferrite of formula CuFe2O4, NiFe2O4, CoFe2O4, and MnFe2O4 deposited on mesoporous silica. A method of preparing the nanotherapeutic that involves mixing a metal(II) salt and a Fe(III) salt with the mesoporous silica nanoparticles to form a powdery mixture, calcining the powdery mixture to form the nanoformulation, and mixing the nanoformulation with the platinum complex. A method for treating cancer with the nanotherapeutic.

Abstract: A Transdermal Drug Delivery System (TDDS) of the reservoir or plaster type for administrating clobazam for the treatment of various types of anxiety and epilepsy, for 1 day, 2 day, 3 day, 4 day, 5 day, 6 day and/or 7-day continuous application.

Abstract: Cannabinoid oil compositions may be used to treat gastrointestinal disorders. An example of the composition is an oral multiparticulate dosage form including a plurality of individual particulates including a solid core with an effective amount of cannabinoid oil bound in microcrystalline cellulose therein and an enteric coating over the solid core.

Abstract: The current disclosure relates to a combination of ingredients including Plumeria alba (Frangipani) flower extract and salicylic acid. The composition can further contain hydroxyacetophenone, titanium dioxide, and/or carrageenan. This combination of components has been shown to be useful as a cleansing composition that is effective for reducing sebum, increasing clarity of the skin, and for improving the appearance of the skin by reducing shine and pore size. This combination of components has further been shown to be useful for reducing irritation and inflammation in the skin.

Abstract: An object of the present invention is to provide a method for stabilizing a substance DFP-11207 sensitive to humidity and unstable at high humidity, and a stabilized preparation thereof, and more specifically, provide a capsule preparation for treating cancer, containing DFP-11207 or a pharmaceutically acceptable salt thereof and a hygroscopic agent.

Abstract: The present invention provides a beverage and a dermatological composition comprising water molecules, the water molecules having oxygen atoms of different isotopes, the beverage being enriched in at least one of the oxygen isotopes, the enrichment being in reference to (i) the amount of that oxygen isotope in the water used to produce the beverage or (ii) the amount of that oxygen isotope in ground water, or (iii) Vienna Standard Mean Ocean Water. The water molecules may be derived from a plant source, such as a juice, a sap or a tree water.

Abstract: Methods related to forming reaction products on surfaces are generally provided. Some methods comprise applying first and second polyelectrolytes in first and second polyelectrolyte carrier fluids to a surface. The first and second polyelectrolytes may be different, and the first and second carrier fluids may be the same or different. Some methods comprise forming a mixture of the first and second polyelectrolytes in a mixture carrier fluid that comprises the first and/or second carrier fluids. The first and second polyelectrolyte may be removed from the mixture carrier fluid to form a reaction product on the surface. In some embodiments, the mixture carrier fluid comprises a salt with a molecular weight of less than or equal to 1 kg/mol at a concentration within the mixture carrier fluid of from 0.01 M to 0.5 M. In some embodiments, the mixture carrier fluid has a turbidity of greater than or equal to 10 NTU and a viscosity of less than or equal to 1 Pa*s.